Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury

Hepatology

Volumn 52, Issue 1, 2010, Pages 303-312

  Lucena, M Isabel ^a,i   García Martín, Elena ^b,j   Andrade, Raúl J ^a,i   Martínez, Carmen ^b,j   Stephens, Camilla ^a,i   Ruiz, Jhon D ^b,j   Ulzurrun, Eugenia ^a,i   Fernandez, M Carmen ^c   Romero Gomez, Manuel ^d,i   Castiella, Augustin ^e   Planas, Ramon ^f,i   Durán, José Antonio ^g   De Dios, Ana Melcón ^g   Guarner, Carlos ^h,i   Soriano, German ^h,i   Borraz, Yolanda ^a,i   Agundez, José A G ^b,j  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c HOSPITAL TORRECÁRDENAS   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e HOSPITAL DE MENDARO   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j Red de Investigación de Reacciones Adversas A Alergenos y Fármacos RIRAAF   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMOXICILLIN PLUS CLAVULANIC ACID; AURAMINE; EPOXIDE; GENOMIC DNA; GLUTATHIONE PEROXIDASE; LEUCINE; MITOCHONDRIAL ENZYME; QUINONE DERIVATIVE; RADICAL; SULFADIAZINE; SUPEROXIDE DISMUTASE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CHOLESTATIC HEPATITIS; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; IDIOSYNCRATIC DRUG INDUCED LIVER INJURY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; METABOLITE; MITOCHONDRION; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; DRUG-INDUCED LIVER INJURY; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; LEUCINE; MALE; MIDDLE AGED; MITOCHONDRIA; POLYMORPHISM, GENETIC; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 77954236608     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23668     Document Type: Article

References (27)

1. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-499.
2. DeLeve LD. Risk factors for drug-induced liver disease. In: Kaplowitz N, DeLeve LD (eds.) Drug-induced liver disease. New York: Informa Healthcare, 2007;291-305.
3. Krähenbühl S. Mitochondria: important target for drug toxicity? J Hepatol 2001;34:334-336.
4. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003;13:145-157. (Pubitemid 36324244)
5. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007;47:128-134.
6. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci 2000;57:1825-1835.
7. Hamanishi T, Furuta H, Kato H, Asako Doi1, Masanori Tamai1, Hiroko Shimomura, et al. Functional variant in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese type 2 diabetic patients. Diabetes 2004;53:2455-2460. (Pubitemid 39145603)
8. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521.
9. Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990;11:272-276.
10. Oslo: World Health Organisation (2005). World Health Organisation Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical (ATC) classification index including defined daily dose (DDDs) for plain substances.
11. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, et al. A comprehensive listing of bioactivation pathways of organic functional groups. Current Drug Metabolism 2005;6:161-225. (Pubitemid 40753853)
12. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35:325-361. (Pubitemid 40691298)
13. Boelsterli UA, Lim PLK. Mitochondrial abnormalities: a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 2007;220:92-107.
14. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65:166-176.
15. Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 2007;150:808-815. (Pubitemid 46440210)
16. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001;52:489-499.
17. Lucena MI, Andrade RJ, Martínez C, Ulzurrun E, García-Martín E, Borraz Y, et al. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. HEPATOLOGY 2008;48:588-596.
18. Andrade RJ, Agúndez JA, Lucena MI, Martínez C, Cueto R, García-Martín E. Pharmacogenomics in drug induced liver injury. Curr Drug Metab 2009;10:956-970.
19. Ong MMK, Latchoumycandane C, Boelsterli UA. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 2007;97:205-213. (Pubitemid 47072169)
20. Fujimoto K, Kumagai K, Ito K, Arakawa S, Ando Y, Oda S, et al. Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicol Pathol 2009;37:193-200.
21. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 2005;59:143-148.
22. Kowald A, Lehrach H, Klipp E. Alternative pathways as mechanism for the negative effects associated with overexpression of superoxide dismutase. J Theor Biol 2006;238:828-840. (Pubitemid 43175833)
23. Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, Koishi R, et al. A study to survey susceptible genetic factors responsible for troglitazone- associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2003;73:435-455. (Pubitemid 36549828)
24. Uetrecht J. Idiosynctratic drug reactions: past, present and future. Chem Res Toxicol 2008:21:84-92. (Pubitemid 351219710)
25. Kashimshetty R, Desai VG, Kale VM, Lee T, Moland CL, Branham WS, et al. Underlying mitochondrial dysfunction triggers flutamideinduced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2009;238:150-159.
26. Sokol RJ, Dahl R, Devereaux MW, Yerushalmi B, Kobak GE, Gumpricht E. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J Pediatr Gastroenterol Nutr 2005;41:235-243. (Pubitemid 41099374)
27. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. HEPATOLOGY 2009;49:2001-2009.